Eyetech Pharmaceuticals at no opinion by Merrill

Eyetech Pharmaceuticals Inc. was changed to a no opinion rating from neutral by Merrill Lynch analysts Eric Ende, Thomas J. McGahren and David Munno on news OSI Pharmaceuticals will acquire the company for $890 million. The analysts said the stock is no longer trading on fundamentals. Eyetech stock closed Monday up $4.14, or 29.59%, at $18.13 on volume of 42,698,213 shares versus a three-month trailing average of 4,721,860 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.